According to an exploratory analysis of data from the POSEIDON trial, patients with non–small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings.

中文翻译：

---

探索 NSCLC 中的突变 KRAS、STK11、KEAP1

根据对 POSEIDON 试验数据的探索性分析，患有 KRAS、STK11 或 KEAP1 突变的非小细胞肺癌患者在使用 tremelimumab 和 durvalumab 联合化疗的三药组合中比单独化疗效果更好。然而，样本量较小，无法对研究结果进行任何明确的解释。